Cytokines as endogenous pyrogens

Journal of Infectious Diseases

Volumn 179, Issue SUPPL. 2, 1999, Pages

  Dinarello, Charles A ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; PYROGEN; TUMOR NECROSIS FACTOR;

BODY TEMPERATURE; CONFERENCE PAPER; CYTOKINE PRODUCTION; FEVER; IMMUNE RESPONSE; MACROPHAGE ACTIVATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0033377587     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513856     Document Type: Conference Paper

References (118)

1. 1. Atkins E. Pathogenesis of fever. Physiol Rev 1960; 40:580-646.
2. 2. Atkins E, Feldman JD, Francis L, Hursh E. Studies on the mechanism of fever accompanying delayed hypersensitivity: the role of the sensitized lymphocyte. J Exp Med 1972; 135:1113-32.
3. 3. Atkins E. Fever: the old and the new. J Infect Dis 1984; 149:339-48.
4. 4. Atkins E. Fever: historical perspectives and evolution of modern views. J Rheumatol 1985; 24(suppl):1-5.
5. 5. Murphy PA, Chesney PJ, Wood WB Jr. Further purification of rabbit leukocyte pyrogen. J Lab Clin Med 1974; 83:310-22.
6. 6. Dinarello CA, Goldin NP, Wolff SM. Demonstration and characterization of two distinct human leukocytic pyrogens. J Exp Med 1974; 139: 1369-81.
7. 7. Cebula TA, Hanson DF, Moore DM, Murphy PA. Synthesis of four endogenous pyrogens by rabbit macrophages. J Lab Clin Med 1979; 94:95-105.
8. 8. Dinarello CA, Renfer L, Wolff SM. Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci USA 1977; 74:4624-7.
9. 9. Merriman CR, Pulliam LA, Kampschmidt RF. Comparison of leukocytic pyrogen and leukocytic endogenous mediator. Proc Soc Exp Biol Med 1977; 154:224-7.
10. 10. Kampschmidt RF. Leukocytic endogenous mediator/endogenous pyrogen. In: Powanda MC, Canonico PG, eds. Physiologic and metabolic responses of the host. Amsterdam: Elsevier/North Holland, 1981:55-74.
11. 11. Gery I, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s). J Exp Med 1972; 136:143-55.
12. 12. Dinarello CA, Renfer L, Wolff SM. Production of antibody against human leukocytic pyrogen. J Clin Invest 1977; 60:465-72.
13. 13. Rosenwasser LM, Dinarello CA, Rosenthal AS. Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J Exp Med 1979; 150:709-14.
14. 14. Murphy PA, Simon PL, Willoughby WF. Endogenous pyrogens made by rabbit peritoneal exudate cells are identical with lymphocyte-activating factors made by rabbit alveolar macrophages. J Immunol 1980; 124: 2498-501.
15. 15. Dinarello CA, Rosenwasser LJ. Lymphocyte activating property of human leukocytic pyrogen. In: Hadden J, Chedid L, Mullen D, Spreafico F, eds. Advances in immunopharmacology. Oxford: Pergamon Press, 1981:419-25.
16. 16. Lachman LB. Interleukin-1; release from LPS-stimulated mononuclear phagocytes. In: Nowotny A, ed. Beneficial effects of endotoxin. New York: Plenum, 1983:283-305.
17. 17. Gordon AH, Parker ID. A pyrogen derived from human white cells which is active in mice. Br J Exp Pathol 1980; 61:534-9.
18. 18. Sztein MB, Vogel SN, Sipe JD, et al. The role of macrophages in the acute-phase response: SAA inducer is closely related to lymphocyte activating factor and endogenous pyrogen. Cell Immunol 1981; 63: 164-76.
19. 19. Beer DJ, Dinarello CA, Rosenwasser LJ, Rocklin RE. Cell-cell interactions in the expression of histamine-induced suppressor cell activity. In: Dixon FJ, Meischer PA, eds. VIII International Symposium on Immunopathology. New York: Academic Press, 1982:77-92.
20. 20. Dinarello CA. Interleukin-1. Rev Infect Dis 1984; 6:51-95.
21. 21. Root RK, Nordlund JJ, Wolff SM. Factors affecting the quantitative production and assay of human leukocytic pyrogen. J Lab Clin Med 1970; 75:679-93.
22. 22. Lachman LB. Human interleukin 1: purification and properties. Fed Proc 1984; 42:2639-45.
23. 23. Lomedico PT, Gubler R, Hellmann CP, et al. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 1984; 312: 458-62.
24. 24. Auron PE, Webb AC, Rosenwasser LJ, et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci USA 1984; 81:7907-11.
25. 25. Van Damme J, De Ley M, Opdenakker G, Billiau A, De Somer P. Homogeneous interferon-inducing 22K factor is related to endogenous pyrogen and interleukin-1. Nature 1985; 314:266-8.
26. 26. Dinarello CA, Cannon JG, Mier JW, et al. Multiple biological activities of human recombinant interleukin 1. J Clin Invest 1986; 77:1734-9.
27. 2 in brain but not in peripheral blood mononuclear cells. Brain Res 1991; 562:199-206.
28. 28. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163:1433 -50.
29. 29. Shapiro L, Zhang XX, Rupp RG, Wolff SM, Dinarello CA. Ciliary neurotrophic factor is an endogenous pyrogen. Proc Natl Acad Sci USA 1993; 90:8614-8.
30. 30. Blatteis CM, Bealer SL, Hunter WS, Llanos QJ, Ahokas RA, Mashburn TA Jr. Suppression of fever after lesions of the anteroventral third ventricle in guinea pigs. Brain Res Bull 1983; 11:519-26.
31. 31. Stitt JT. Evidence for the involvement of the organum vasculosum laminae terminalis in the febrile response of rabbits and rats. J Physiol 1985; 368:501-11.
32. 31a. Dascombe MJ. Cyclic nucleotides and fever. In: Milton AS, ed. Pyretics and antipyretics. Heidelberg, Germany: Springer-Verlag, 1982:219-55.
33. 32. Rossi V, Breviario F, Ghezzi P, Dejana E, Mantovani A. Prostacyclin synthesis induced in vascular cells by interleukin-1. Science 1985; 229: 174-6.
34. 33. Bevilacqua MP, Pober MS, Wheeler ME, Cotran RS, Gibrone MA Jr. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest 1985; 76:2003-11.
35. 34. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL-1 and Interferon-γ: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986; 137: 245-54.
36. 2 in cerebrospinal fluid of afebrile and febrile cat. Am J Physiol 1983; 244:R785-93.
37. 36. Dejana E, Breviario F, Erroi A, et al. Modulation of endothelial cell functions by different molecular species of interleukin 1. Blood 1987; 69:695-9.
38. 37. Pacák F, Siegert R. Chemical characterization of a rabbit leukocytic pyrogen. Eur J Biochem 1982; 127:375-80.
39. 38. Saklatvala J, Sarsfield SJ, Townsend Y. Pig interleukin 1: purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J Exp Med 1985; 162: 1208-22.
40. 39. Hanson DF, Murphy PA. Demonstration of interleukin 1 activity in apparently homogeneous specimens of the pI 5 form of rabbit endogenous pyrogen. Infect Immun 1984; 45:483-90.
41. 3H-leu-labeled human monocyte interleukin-1 with endogenous pyrogen activity. Br J Rheumatol 1985; 24(suppl):59-64.
42. 41. Knudsen PJ, Dinarello CA, Strom TB. Purification and characterization of a unique human interleukin 1 from the tumor cell line U937. J Immunol 1986; 136:3311-6.
43. 42. Wolff SM, Mulholland JH, Ward SB. Quantitative aspects of the pyrogenic response of rabbits to endotoxin. J Lab Clin Med 1965; 65:268-76.
44. 43. Kitamura T, Takaku F. A preclinical and phase I clinical trial of IL-1. J Exp Med 1989; 7:170-7.
45. 44. Laughlin MJ, Kirkpatrick G, Sabiston N, Peters W, Kurtzberg J. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase I clinical trials of colony stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, and M-CSF. Ann Hematol 1993; 67:267-76.
46. 45. Tewari A, Buhles WC Jr, Starnes HF Jr. Preliminary report: effects of interleukin-1 on platelet counts. Lancet 1990; 336:712-4.
47. 46. Nemunaitis J, Appelbaum FR, Lilleby K, et al. Phase I study of recombinant interleukin-1β in patients undergoing autologous bone marrow transplantation for acute myelogenous leukemia. Blood 1994; 83: 3473-9.
48. 47. Crown J, Jakubowski A, Gabrilove J. Interleukin-1: biological effects in human hematopoiesis. Leuk Lymphoma 1993; 9:433-40.
49. 48. Smith JW2, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992; 10:1141-52.
50. 49. Iizumi T, Sato S, Iiyama T, et al. Recombinant human interleukin-1 beta analogue as a regulator of hematopoiesis in patients receiving chemotherapy for urogenital cancers. Cancer 1991; 68:1520-3.
51. 50. Smith JW, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992; 10:1141-52.
52. 51. Smith JW, Longo D, Alford WG, et al. The effects of treatment with interleukin-1α on platelet recovery after high-dose carboplatin. N Engl J Med 1993; 328:756-61.
53. 52. Crown J, Jakubowski A, Kemeny N, et al. A phase I trial of recombinant human interleukin-1β alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 1991; 78:1420-7.
54. 53. van der Poll T, Bueller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322:1622-7.
55. 54. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (1L-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994; 83:113-8.
56. 55. Tilg H, Atkins MB, Dinarello CA, Mier JW. Induction of circulating interleukin-10 by interleukin-1 and interleukin-2, but not interleukin-6 immunotherapy. Cytokine 1995; 7:734-9.
57. 56. Bargetzi MJ, Lantz M, Smith CG, et al. Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding proteins. Cancer Res 1993; 53:4010-3.
58. 57. Beutler B, Cerami A. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 1986; 320:584-8.
59. 2 production in resting macrophages. Biochem Biophys Res Commun 1986; 136:94-101.
60. 59. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320:265-71.
61. 60. Lonnemann G, Endres S, Van der Meer JW, Cannon JG, Koch KM, Dinarello CA. Differences in the synthesis and kinetics of release of interleukin 1 alpha, interleukin 1 beta, and tumor necrosis factor from human mononuclear cells. Eur J Immunol 1989; 19:1531-6.
62. 61. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75:40-7.
63. 62. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264:11974-80.
64. 63. Novick D, Engelmann H, Wallach D, Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med 1989; 170: 1409-14.
65. 64. Zilberstein A, Riggieri R, Korn JH, Revel M. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J 1986; 5:2529-37.
66. 65. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83-5.
67. 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987; 84:7251-6.
68. 67. Van Oers MHJ, Van Der Heyden AAPAM, Aarden LA. Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clin Exp Immunol 1988; 71:314-9.
69. 68. Nijsten MW, De Groot ER, ten Duis HJ, Klasen HJ, Hack CE, Aarden LA. Serum levels of interleukin-6 and acute phase responses [letter]. Lancet 1987; 2:921.
70. 2), as a B cell hybridoma/ plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med 1987; 165:914-9.
71. 69a. Bunning RAD, Russell RGG, Van Damme J. Independent induction of interleukin-6 and prostaglandin E2 by interleukin-1 in human articular chondrocytes. Biochem Biophys Res Commun 1990; 166:1163-70.
72. 70. Biliau A, Heine JW, Van Damme J, Heremans H, De Somer P. Tolerability of pure fibroblast interferon in man. Ann NY Acad Sci 1980; 350: 374-5.
73. 71. Biliau A. Pharmacokinetic and pharmacological aspects of interferon therapy in man. Acta Microbiol Acad Sci Hung 1981; 28:257-62.
74. 72. Bocci V. Possible causes of fever after interferon administration. Biomedicine 1980; 32:159-62.
75. 73. Horning SJ, Levine JF, Miller RA, Rosenberg SA, Merigan TC. Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. JAMA 1982; 247:1718-22.
76. 74. Dinarello CA, Bemheim HA, Duff GW, et al. Mechanisms of fever induced by recombinant human interferon. J Clin Invest 1984; 74:906-13.
77. 75. Lane HC, Fauci AS. Immunologic reconstitution in the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103:714-8.
78. 76. Kurzrock R, Quesada JR, Rosenblum MG, Sherwin SA, Gutterman JU. Phase I study of iv administered recombinant gamma interferon in eight patients with advanced cancer. Cancer Treat Res 1986; 70:1357-64.
79. 77. Dinarello CA, Ikejima T, Warner SJ, et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 1987; 139:1902-10.
80. 78. Ghezzi P, Dinarello CA. IL-1 induces IL-1. III. Specific inhibition of IL-1 production by IFN-gamma. J Immunol 1988; 140:4238-44.
81. 79. Schindler R, Ghezzi P, Dinarello CA. IL-1 induces IL-1. IV. IFN-γ suppresses IL-1 but not lipopolysaccharide-induced transcription of IL-1. J Immunol 1990; 144:2216-22.
82. 80. Schindler R, Dinarello CA. A method for removing interleukin-1 - and tumor necrosis factor-inducing substances from bacterial cultures by ultrafiltration with polysulfone. J Immunol Methods 1989; 116:159-65.
83. 81. Lotze MT, Matory YL, Rayner AA, et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58:2764-72.
84. 82. Atkins MB, Gould JA, Allegretta M, et al. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol 1986; 4:1380-91.
85. 83. Nedwin GE, Svdersky LP, Bringman TS, Palladino MA Jr, Goeddel DV. Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. J Immunol 1985; 135:2492-7.
86. 84. Mier JW, Souza LM, Allegretta M, Boone T, Bemheim HA, Dinarello CA. Dissimilarities between purified human interleukin-1 and recombinant human interleukin-2 in the induction of fever, brain prostaglandin, and acute-phase protein synthesis. J Biol Response Modif 1985; 4:35-45.
87. 85. Mier JW, Vachino G, Van der Meer JW, et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 1988; 8:426-36.
88. 86. Snell ES, Atkins E. The presence of endogenous pyrogen in normal rabbit tissues. J Exp Med 1965; 121:1019-38.
89. 87. Atkins E, Bodel P, Francis L. Release of an endogenous pyrogen in vitro from rabbit mononuclear cells. J Exp Med 1967; 126:357-84.
90. 88. Bodel P, Atkins E. Release of endogenous pyrogen by human monocytes. N Engl J Med 1967; 276:1002-13.
91. 89. Hahn HH, Char DC, Postel WB, Wood WB Jr. Studies on the pathogenesis of fever. XV. The production of endogenous pyrogen by peritoneal macrophages. J Exp Med 1967; 126:385-94.
92. 90. Hanson DF, Murphy PA, Windle BE. Failure of rabbit neutrophils to secrete endogenous pyrogen when stimulated with staphylococci. J Exp Med 1980; 151:1360-71.
93. 91. Windle BE, Murphy PA, Cooperman S. Rabbit polymorphonuclear leukocytes do not secrete pyrogens of interleukin 1 when stimulated by endotoxin, polyinosine:polycytosine, or muramyl dipeptide. Infect Immun 1983; 39:1142-6.
94. 92. Tiku K, Tiku ML, Skosey JL. Interleukin 1 production by human polymorphonuclear neutrophils. J Immunol 1986; 136:3677-85.
95. 93. Canning PC, Neill JD. Isolation and characterization of interleukin-1 from bovine polymorphonuclear leukocytes. J Leukoc Biol 1989; 45: 21-8.
96. 94 Goh K, Furusawa S, Kawa Y, Negishi-Okitsu S, Mizoguchi M. Production of interleukin-1 alpha and beta by human peripheral polymorphonuclear neutrophils. Int Arch Allergy Appl Immunol 1989; 88:297-303.
97. 95. Goto F, Goto K, Ohkawara S, et al. Purification and partial sequence of rabbit polymorphonuclear leukocyte-derived lymphocyte proliferation potentiating factor resembling IL-1 beta. J Immunol 1988; 140:1153-8.
98. 96. Mori S, Goto F, Goto K, et al. Cloning and sequence analysis of a cDNA for lymphocyte proliferation potentiating factor of rabbit neutrophils: identification as rabbit interleukin-1/β. Biochem Biophys Res Commun 1988; 150:1237-43.
99. 97. Goto F, Nakamura S, Goto K, Yoshinaga M. Generation of an interleukin-1 - like lymphocyte-stimulating factor at inflammatory sites: correlation with the infiltration of polymorphonuclear leukocytes. Br J Exp Pathol 1984; 65:521-32.
100. 98. Sheng YJ, Bird J, Pompidou A, Florentin I, Giroud JP. Rat and human polymorphonuclear leukocyte derived lymphocyte stimulatory factors. Biomed Pharmacother 1984; 38:304-8.
101. 99. Ohkawara S, Goto K, Mori S, et al. Interleukin-1 production by polymorphonuclear leukocytes during the course of acute inflammation in rabbits. Dermatologica 1989; 179:84-90.
102. 100. Bell TV, Harley CB, Stetsko D, Sauder DN. Expression of mRNA homologous to interleukin 1 in human epidermal cells. J Invest Dermatol 1987; 88:375-9.
103. 101. Libby P, Ordovas JM, Birinyi LK, Auger KR, Dinarello CA. Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest 1986; 78:1432-8.
104. 102. Libby P, Ordovas JM, Auger KR, Robbins AH, Birinyi LK, Dinarello CA. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol 1986; 124:179-85.
105. 103. Rambaldi A, Torcia M, Bettoni S, et al. Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood 1991; 78:3248-53.
106. 104. Cozzolino F, Torcia M, Aldinucci D, et al. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989; 74:380-7.
107. 105. Scala G, Kuang YD, Hall RE, Muchmore AV, Oppenheim JJ. Accessory cell function of human B cells. I. Production of both interleukin 1-like activity and an interleukin 1 inhibitory factor by an EBV-transformed human B cell line. J Exp Med 1984; 159:1637-52.
108. 106. Scala G, Allavena P, Djeu JY, et al. Human large granular lymphocytes are potent producers of interleukin-1. Nature 1984; 309:56-9.
109. 107. Sauder DN. Biologic properties of epidermal cell thymocyte-activating factor (ETAF). J Invest Dermatol 1985; 85(suppl 1):176S-9S.
110. 108. Bodel P, Ralph P, Wenc K, Long JC. Endogenous pyrogen production by Hodgkin's disease and human histiocytic lymphoma cell lines in vivo. J Clin Invest 1980; 65:514-8.
111. 109. Lovett DH, Sterzel RB, Ryan JL, Atkins E. Production of an endogenous pyrogen by glomerular mesangial cells. J Immunol 1985; 134:670-2.
112. 110. Cannon JG, Van der Meer JW, Kwiatkowski D, et al. Interleukin-1 beta in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res 1988; 7:457-67.
113. 111. Granowitz EV, Santos A, Poutsiaka DD, et al. Circulating interleukin-1 receptor antagonist levels during experimental endotoxemia in humans. Lancet 1991; 338:1423-4.
114. 112. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161:79-84.
115. 113. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988; 2:706-9.
116. 114. Fisher CJJ, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22:12-21.
117. 115. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
118. 116. Fantuzzi G, Dinarello CA. The inflammatory response in interleukin-1/β-deficient mice: comparison with other cytokine-related knock-out mice. J Leukoc Biol 1996; 59:489-93.